Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmacology Fall 2015 > L 29-30 > Flashcards

L 29-30 Flashcards

1
Q

Causes of low output CHF

A 
CAD
HT
MI
Persistent Arrhythmias
Rheumatic HD
General Cardiomyopathy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

CHF and RAAS

A

Poor CO => poor renal perfusion=> production of Renin and activation of RAAS to increase blood volume

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

CHF and SNS

A

Poor CO=> decreased systolic BP=> neurohumoral response=> increase in HR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

CHF and preload

A

In CHF preload on the heart is increased due to increased blood volume from the RAAS system and increased SNS tone.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

CHF and afterload

A

In CHF afterload rises from RAAS and increased SNS tone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

CHF and contractility

A

Contractility is decreased as ventricles dilate and stretch farther than normal.
Contractility increased by positive inotropic agents and worsened by Beta blockers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Equation for CO

A

CO= HR x SV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

CHF and HR

A

Heart Rate is generally increased because reduced CO=> baroreflex=> increased SNS tone causing increased HR.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Factors controlling contractility

A

Sensitivity of contractility proteins to Ca
Amount of Ca released from SR
Amount of Ca stored in SR
Amount of trigger Ca
Activity of Na-Ca exchanger
Intracellular Na concentration and activity of Na-K ATPase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Explain cardiac myocyte electrolyte transport and activity at the cell membrane

A

Na/K ATPase maintains a high Na concentration outside the cell. This gradient is used to exchange Na into the cell for Ca out of the cell.
Ca is allowed into the cell and to act as trigger Ca by L-type voltage-gated Ca channels.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Site of action for cardiac glycosides

A

NA/K–ATPase in the cardiac myocyte

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe Ca channels in the SR of the heart

A

SERCA: A Ca ATPase that transports Ca into the SR
RyR: (ryanodine receptor) Ca gated Ca channel that releases Ca from the SR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Main goals of drug treatment in CHF and drug classes used for each

A

1) Reduce preload with diuretics and venodilators
2) Reduce afterload with arteriodilators
3) Improve contractility with positive inotropic drugs
4) Decrease HR and energy expenditure of the heart with Beta blockers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are cardiac glycosides?

A

Positive inotropic agents commonly called Digitalis.
Only version of this drug in the US is Digoxin.
These act on the Na/K–ATPase in the cell membrane of cardiac myocyte

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Mechanism of action for cardiac glycosides

A

Digitalis (Digoxin) is a positive inotropic agent that increases contractility by increasing rate of contraction and relaxation.

Digitalis binds to the K+ site of the NA/K–ATPase and prevents function
=> increased intracellular Na
=> decreased Ca expulsion
=> increased intracellular Ca
=> decreased intracellular K & increased actin/myosin interaction=> increased contractility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Potassium and Digitalis interaction

A

K and Digitalis compete for binding site on Na/K–ATPase.
Potassium is a competitive inhibitor of Digitalis and is an effective treatment of Digitalis toxicity.
Potassium is useful in decreasing the automaticity of the heart by pumping more Na out which causes more Ca to also be pumped out=> decreased actin/myosin interaction.

17
Q

Effect of Ca levels and digitalis

A

Ca enhances the effect of Digitalis and therefore should never be used in cases of Digitalis toxicity

18
Q

Digitalis and HR

A

Digitalis will always reduce HR, but it only affects CO in the failing heart, but no effect in the healthy heart.
In failing heart, increased contractility=> increased CO=> decreased baroreceptor response=> decreased SNS tone and decreased HR

19
Q

Digitalis and vascular effects

A

Normal Heart: causes contraction of smooth muscle => vasoconstriction (why there is no change in CO in normal patients despite decrease in HR)

Failing Heart: causes vasodilation due to reduced baroreceptor firing and decreased SNS output

20
Q

Digitalis Pharmacokinetics:

Oral availability, Half-life, Renal elimination

A

Oral Avail: 75%
Half-life: 40 hours
Renal Elim: >80%

21
Q

Adverse effects of Digitalis in GI tract

A

Anorexia, diarrhea, vomiting, abdominal pain

22
Q

Earliest signs of digitalis intoxication

A

GI symptoms as well as copius salivation

23
Q

How safe is Digitalis?

A

Has a narrow margin of safety– therapeutic dose is 50% of toxic dose. Toxicity is common. Most severe effect is cardiac toxicity leading to death.

24
Q

Adverse effects of Digitalis

A

Most serious effects are cardiac: Bradycardia, Ectopic ventricular beats, AV block, Bigeminy (PVB’s, T-wave inversion, ST depression)

25
Q

Digitalis drug interactions

A

Diuretics: loop and thiazide cause hypokalemia=> enhanced effects
Beta blockers: decrease SA and AV node conduction predisposing for AV block
Ca Channel antagonists: decrease contractility
Catecholamines: sensitize myocardium to digoxin

26
Q

Name Phosphodiesterase inhibitors (bipyridines) and how they work.

A

Inamrinone & Milrinone

Inodilators: meaning they are inotropic and vasodilators

Work by inhibiting cAMP phosphodiesterase in cardiac and vascular muscle which usually breaks down cAMP.

Helps by improving diastole and contractility along with vasodilation.

27
Q

Use of bipyridines

A

Not used often. Not shown to be safe or effective in long-term treatment of heart failure.

28
Q

Name positive inotropic sympathomimetic agents

A

Dopamine
Dobutamine
Calcium Sensitizers

29
Q

Dopamine use as inotropic agent

A

Used in severe refractory CHF
Low doses=> increased CO (pos inotropic effect) and increased renal perfusion
Lowers peripheral resistance
Enhances Na excretion

30
Q

Dobutamine characteristics

A

Selective beta-1 agonist

Positive inotropic with less tachycardia

31
Q

Classes of drugs used for CHF that don’t have a positive inotropic effect.

A

1) Diuretics
2) ACE inhibitors
3) Beta Blockers
4) Vasodilators

32
Q

Name potassium sparing diuretics used in CHF

A

Amiloride: inhibits ENaK function in principle cells, can lead to hyperkalemia when combined withACE inhibitors or ANG II antagonists

Spironolactone: also inhibits aldosterone receptors

33
Q

Explain B type natriuretic peptide

A

hBNP: produced by ventricular muscle, prepared for use in acute treatment of decompensated CHF.
Works to reduce pulmonary capillary wedge pressure and relieve CHF symptoms of fatigue and dyspnea
Monitor closely to prevent hypotension

34
Q

What is pulmonary capillary wedge pressure?

A

Pressure measured in a pulmonary artery that is used to estimate the pressure in the left atrium. Elevations indicate failure of the left ventricle and backup of pressure into the atrium.

35
Q

Three general effects of Angiotensin II

A

1) Vasoconstriction and increase rate of pressor response
2) Altered kidney function (increase Na absorption, aldosterone release and effects, renal vasoconstriction)
3) Cardiac and vascular remodeling (increased growth hormone production, increased ECM production, increased vascular tension)

36
Q

Why/how are ACE inhibitors and ANG II antagonists helpful in CHF?

A

Both reduce RAAS.
This is helpful because it decreases the afterload on the heart from vasoconstriction by ANG II and it decreases the preload by inhibiting aldosterone release and increased fluid retention.

37
Q

Beta blocker use in CHF

A

Dangerous because of neg inotropic effect

Useful to enhance diastolic function and ejection fraction. Also reduces cardiac remodeling.

38
Q

Vasodilators used for CHF

A

Sodium Nitroprusside: IV administration for acutely decompensated CHF, dilates both arteries and veins, can cause hypotension

Nitroglycerin or Isosorbide Dinitrate: orally, dilates veins more than arteries, tolerance develops

Hydralazine: relaxes arteriolar smooth muscle=> reflex increase in HR, increase CO, Increase LV ejection fraction, tolerance can develop

Long term use of hydralazine and isosorbide dinitrate can reduce damaging remodeling of the heart

Pharmacology Fall 2015 (12 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions